Skip to main content
TipRanks
Go Ultimate75% OFF

AnaptysBio (0HFQ) Share Price & Analysis

1 Followers

0HFQ Stock Chart & Stats

$46.91-$0.89(-1.86%)
At close: 4:30 PM GMT
$45$50$55Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$45.76 - $47.32
52-Week Range
$33.38 - $73.09
Previous Close
$47.80
Volume
N/A
Average Volume (3M)
159
Market Cap
$1.41B
Enterprise Value
$1.87B
Total Cash (Recent Filing)
$152.99M
Total Debt (Recent Filing)
$12.57M
Price to Earnings (P/E)
7.3
Beta
1.20
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Current Profitability

The latest results show a substantial profitability inflection, with strong net income and operating margins. If this earnings improvement is supported by collaboration economics and licensing activity, it can provide meaningful internal funding capacity and improve strategic flexibility over the next several quarters.

Cash Generation Turnaround

Positive operating and free cash flow represent a material improvement from the company’s earlier cash-burning period. Strong cash conversion in the latest TTM can reduce reliance on external financing and provide greater flexibility to advance antibody programs or pursue partnerships.

Antibody Platform And Partnering Model

An antibody discovery and engineering platform gives AnaptysBio a defined basis for developing biologic candidates in immune and inflammatory diseases. Its ability to partner or out-license programs also provides a route to monetize development work without relying solely on future product sales.

Bears Say

Revenue Contraction

Revenue contraction weakens confidence that the latest profit level represents a steadily expanding operating base. For a company relying on collaboration and licensing economics, lower revenue can signal uneven deal timing or reduced commercial contribution, making future earnings and cash generation less predictable.

Thin Equity Cushion

The very small equity base leaves the company financially sensitive to changes in reported equity, even though absolute debt is relatively low. This thin cushion can constrain capital allocation and increase financial fragility if operating results weaken or additional funding becomes necessary.

History Of Cash Burn

The recent cash-flow improvement has not yet established a long, stable record of self-funding. Prior multi-year cash burn indicates that operating performance can be highly variable, which may require renewed reliance on collaborations or external financing if profitability and cash conversion deteriorate.

AnaptysBio News

0HFQ FAQ

What was AnaptysBio’s price range in the past 12 months?
AnaptysBio lowest share price was $33.38 and its highest was $73.09 in the past 12 months.
What is AnaptysBio’s market cap?
AnaptysBio’s market cap is $1.41B.
When is AnaptysBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were AnaptysBio’s earnings last quarter?
AnaptysBio released its earnings results on Mar 09, 2027. The company reported $5.11 earnings per share for the quarter.
Is AnaptysBio overvalued?
According to Wall Street analysts AnaptysBio’s price is currently Undervalued.
Does AnaptysBio pay dividends?
AnaptysBio does not currently pay dividends.
What is AnaptysBio’s EPS estimate?
AnaptysBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AnaptysBio have?
AnaptysBio has 29,729,847 shares outstanding.
What happened to AnaptysBio’s price movement after its last earnings report?
AnaptysBio reported an EPS of $5.11 in its last earnings report. Following the earnings report the stock price went down -4.088%.
Which hedge fund is a major shareholder of AnaptysBio?
Hedge funds hold AnaptysBio shares: the largest hedge-fund position in AnaptysBio is 563,784,119 shares, and hedge funds increased their holdings by 487.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology